Zhengye Biotechnology Holding (ZYBT) Other Non-Current Liabilities (2024)
Zhengye Biotechnology Holding's (ZYBT) quarterly Other Non-Current Liabilities came in at $20325.5 in Q4 2024.
Powered by 
Analysis
Zhengye Biotechnology Holding (ZYBT) Other Non-Current Liabilities (2024) Analysis & Trends
Zhengye Biotechnology Holding (ZYBT) has reported Other Non-Current Liabilities for 1 consecutive years, with $20325.5 the latest figure, recorded in Q4 2024.
- On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $20325.5 in Q4 2024; TTM through Dec 2024 was $20325.5, a N/A change from a year earlier, with the FY2024 full-year figure at $20000.0, changed N/A from the prior year.
- Other Non-Current Liabilities was $20325.5 for Q4 2024 at Zhengye Biotechnology Holding.
- Over five years, Other Non-Current Liabilities peaked at $20325.5 in Q4 2024 and troughed at $20325.5 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.52 Bn | 40.33 Bn | 779.09 Mn |
| 2 | Zoetis | 30.69 Bn | 29.02 Bn | 1.05 Bn |
| 3 | Elanco Animal Health | 11.89 Bn | 11.36 Bn | 798.00 Mn |
| 4 | Phibro Animal Health | 1.50 Bn | 1.42 Bn | 134.40 Mn |
| 5 | Immucell | 89.92 Mn | 81.06 Mn | 2.44 Mn |
| 6 | Zhengye Biotechnology Holding | 75.05 Mn | 67.96 Mn | - |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - |